Evidence map›Paper›PMID 40760094›Full record

ArticleOncogene2025

The CIC::DUX4 oncoprotein maintains DNA integrity through direct regulation of the catalytic subunit of DNA polymerase epsilon (POLE).

Zeinab Kosibaty, Cuyler Luck, Ross A Okimoto

Abstract read
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zeinab KosibatyDepartment of Medicine, University of California, San Francisco, CA, USA.
Cuyler LuckDepartment of Medicine, University of California, San Francisco, CA, USA.
Ross A OkimotoDepartment of Medicine, University of California, San Francisco, CA, USA. Ross.Okimoto@ucsf.edu.ORCID http://orcid.org/0000-0002-4467-8476

Funding

Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomasR37CA255453 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Ross Okimoto · 2021 to 2026
$2.7M
Leveraging Retained Partner Gene Function to Effectively Target CIC-rearranged Fusion OncoproteinsF31CA287493 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LUCK, CUYLER · 2024 to 2025
$92k
NCI NIH HHS F31 CA287493NCI NIH HHS R37 CA255453NIGMS NIH HHS T32 GM136547U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1F31CA287493U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 5R37CA255453
6 · The paper itself

Abstract

Transcription factor (TF) fusion oncoproteins represent cancer-specific alterations that arise from chromosomal rearrangements. Through target gene recognition, TF fusions can disseminate transcriptional responses that collectively work to drive tumorigenesis. Thus, identifying the molecular targets that operate as a disease-driving network can potentially uncover key actionable dependencies. We have taken this strategy to dissect the underlying biological mechanism by which CIC::DUX4, a fusion oncoprotein associated with dismal outcomes, drives sarcomagenesis. We and others have defined a CIC::DUX4 fusion-mediated network that dysregulates cell-cycle and DNA replication checkpoints. Specifically, CIC::DUX4-mediated CCNE1 upregulation compromises the G1/S transition, leading to high DNA replication stress and conferring a dependence on the G2/M checkpoint kinase, WEE1. WEE1 provides a molecular brake to enable effective DNA repair prior to mitotic entry. Importantly, the mechanism by which CIC::DUX4 regulates DNA repair remains unknown. Here we show that the catalytic subunit of DNA polymerase epsilon (POLE) is essential for DNA integrity and cellular division in CIC::DUX4 sarcoma. Mechanistically, POLE loss increases DNA damage and induces p21-mediated cellular senescence to limit CIC::DUX4 tumor growth in vitro and tumor formation in vivo. Collectively, we credential POLE as a CIC::DUX4 target and further characterize a functional network through which CIC::DUX4 operates to drive tumor progression and survival.

Indexed as

Homeodomain ProteinsOncogene Proteins, FusionAnimalsCell Cycle ProteinsCell Line, TumorCyclin EDNA DamageDNA RepairDNA ReplicationHumansMiceOncogene ProteinsProtein-Tyrosine KinasesCCNE1 protein, humanCell Cycle ProteinsCyclin EDUX4L1 protein, humanHomeodomain ProteinsOncogene ProteinsOncogene Proteins, FusionProtein-Tyrosine KinasesWEE1 protein, human

Identifiers

PMID40760094
PMCPMC12436161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.